Back to top
more

Genmab (GMAB)

(Delayed Data from NSDQ)

$28.56 USD

28.56
560,041

-0.51 (-1.75%)

Updated Apr 23, 2024 03:59 PM ET

After-Market: $28.54 -0.02 (-0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Genmab A/S Sponsored ADR (GMAB) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

After losing some value lately, a hammer chart pattern has been formed for Genmab A/S Sponsored ADR (GMAB), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

New Strong Buy Stocks for January 17th

SKWD, PHG, BK, PAGS and GMAB have been added to the Zacks Rank #1 (Strong Buy) List on January 17, 2024.

GMAB or TECH: Which Is the Better Value Stock Right Now?

GMAB vs. TECH: Which Stock Is the Better Value Option?

HRMY or GMAB: Which Is the Better Value Stock Right Now?

HRMY vs. GMAB: Which Stock Is the Better Value Option?

AbbVie (ABBV) Lymphoma Drug Gets FDA Breakthrough Therapy Tag

The FDA grants breakthrough therapy designation to AbbVie's (ABBV) Epkinly in follicular lymphoma indication. The EMA validates a regulatory filing seeking label expansion for the drug.

Merus N.V. (MRUS) Soars 5.5%: Is Further Upside Left in the Stock?

Merus N.V. (MRUS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

AbbVie's (ABBV) Epcoritamab Gets Approval in Europe for DLBCL

Tepkinly is AbbVie's (ABBV) second hematological cancer drug to be approved in the European Union. It is also the third blood cancer medicine in AbbVie's portfolio

Seagen's (SGEN) Late-Stage Cervical Cancer Study Meets Goals

Seagen (SGEN) and Genmab announce that the late-stage study of Tivdak in the second-line treatment of adult patients with recurrent or metastatic cervical cancer meets the primary and secondary goals.

PBYI vs. GMAB: Which Stock Should Value Investors Buy Now?

PBYI vs. GMAB: Which Stock Is the Better Value Option?

AbbVie (ABBV) Gets FDA Nod for Lymphoma Drug Epcoritamab

The FDA approves AbbVie's (ABBV) epcoritamab, to be marketed as Epkinly, for relapsed/refractory large B-cell lymphoma, a form of NHL. Epkinly is AbbVie's third blood cancer drug.

Strength Seen in Ultragenyx (RARE): Can Its 6.7% Jump Turn into More Strength?

Ultragenyx (RARE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks.com featured highlights Genmab, Hologic, ServiceNow and Splunk

Genmab, Hologic, ServiceNow and Splunk have been highlighted in this Screen of The Week article.

Sanghamitra Saha headshot

4 Top Stocks to Buy on Earnings Beat Potential

These top-ranked stocks are likely to beat on the bottom line in their next releases. These stocks include Genmab (GMAB), Hologic (HOLX), ServiceNow (NOW) and Splunk (SPLK).

GILD or GMAB: Which Is the Better Value Stock Right Now?

GILD vs. GMAB: Which Stock Is the Better Value Option?

New Strong Buy Stocks for January 11th

GMAB, OSW, ACDC, EVBG and MTG have been added to the Zacks Rank #1 (Strong Buy) List on January 11 , 2023.

Ensign Group (ENSG) Unveils Dividend Hike to Reward Shareholders

Ensign Group's (ENSG) latest dividend hike reflects strong financial standing and intensified focus in the tactical deployment of capital.

LGND or GMAB: Which Is the Better Value Stock Right Now?

LGND vs. GMAB: Which Stock Is the Better Value Option?

Is Elevance Health, Inc. (ELV) Stock Outpacing Its Medical Peers This Year?

Here is how Elevance Health (ELV) and Genmab AS Sponsored ADR (GMAB) have performed compared to their sector so far this year.

Genmab AS Sponsored ADR (GMAB) Hits Fresh High: Is There Still Room to Run?

Genmab AS Sponsored ADR (GMAB) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Ensign Group (ENSG) Facility Buyout to Boost Colorado Foothold

Ensign Group (ENSG) acquires two skilled nursing facilities in Colorado that are likely to grow its healthcare portfolio and solidify its nationwide presence.

Oncolytics Biotech Inc. (ONCY) Hit a 52 Week High, Can the Run Continue?

Oncolytics Biotech Inc. (ONCY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks.com featured highlights include Tap Genmab, KnowBe4, UserTesting, Enphase Energy and Gartner

Tap Genmab, KnowBe4, UserTesting, Enphase Energy and Gartner are part of the Zacks Screen of the Week article.

Sanghamitra Saha headshot

5 Top Stocks to Tap Earnings Beat Potential

Buy shares of Genmab (GMAB), KnowBe4 (KNBE), UserTesting (USER), Enphase Energy (ENPH) and Gartner (IT).

Here's What's Driving AbbVie's (ABBV) Outperformance This Year

AbbVie (ABBV) boasts several new drugs with the potential to drive revenues once Humira loses U.S. exclusivity in 2023. Its early and mid-stage pipeline has several candidates with blockbuster potential.

Is Elevance Health, Inc. (ELV) Outperforming Other Medical Stocks This Year?

Here is how Elevance Health (ELV) and Genmab AS Sponsored ADR (GMAB) have performed compared to their sector so far this year.